ReviewSurgical pathology clinics2025
High-Risk Breast Lesions on Core Biopsy: Rates of Upgrade and Management Recommendations.
Review in Surgical pathology clinics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of high-risk (B3) breast lesions in symptomatic practice: evidence review and practical recommendations for multidisciplinary care.Virchows Archiv : an international journal of pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
High-risk lesions of the breast confer an increased risk for breast cancer. Due to wide variations in the reported rate of upgrade to carcinoma at excision, optimal management of these lesions is controversial. Intraductal papillomas, mucocele-like lesions, radial scars, and complex sclerosing lesions without atypia found on core biopsy do not require excision. Flat epithelial atypia and classic lobular neoplasia can be managed conservatively while nonclassic forms of lobular carcinoma in situ should undergo excision. In most cases, atypical ductal hyperplasia should be surgically excised, though there is a subset of patients for whom nonsurgical management can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.